SAB Biotherapeutics (SABS) Preferred Shares (2023 - 2026)

SAB Biotherapeutics (SABS) has 4 years of Preferred Shares data on file, last reported at $59.0 in Q1 2026.

• Quarterly Preferred Shares rose 1080.0% year-over-year to $59.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $59.0 (up 1080.0% YoY) and the FY2025 annual result came in at $64.0, changed N/A from the prior year.
• Preferred Shares fell to $59.0 in Q1 2026, from $64.0 in the prior quarter.
• In the past five years, Preferred Shares ranged from a high of $64.0 in Q4 2025 to a low of $3.0 in Q3 2025.
• A 4-year average of $17.33 and a median of $5.0 in 2023 frame the typical range for Preferred Shares.
• Annual changes were most pronounced in 2025 — Preferred Shares plunged 40.0% — and 2026, when it surged 1080.0%.
• Tracing SABS's Preferred Shares over 4 years: stood at $5.0 in 2023, then changed by 0.0% to $5.0 in 2024, then surged by 1180.0% to $64.0 in 2025, then slipped by 7.81% to $59.0 in 2026.
• The last three Preferred Shares figures came in at $59.0 (Q1 2026), $64.0 (Q4 2025), and $3.0 (Q3 2025), per Business Quant data.